Centrexion Therapeutics reported positive 6-month efficacy data from the Phase 2b TRIUMPH trial demonstrating durable response of CNTX-4975 for treatment of chronic pain associated with knee osteoarthritis.
REMD Biotherapeutics (REMD Bio) and its subsidiary Cosci-REMD Biotherapeutics (Cosci-REMD Bi) have announced positive results from a phase 1 clinical study of its lead candidate REMD-477 in patients with type 1 diabetes.
Probiodrug has reported positive results for its PQ912 candidate in a Phase 2a SAPHIR study in early Alzheimer’s disease (AD) patients.
Merck, in partnership with Pfizer, announced that two phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help enhance glycemic control in adults with type 2 diabetes, met their primary endpoints.
Teva Pharmaceutical Industries’ Fremanezumab has meets all primary & secondary endpoints across both monthly and quarterly dosing regimens in phase III study in episodic migraine prevention.
Juno Therapeutics has presented updated TRANSCEND NHL 001 trial data showing high durable response rates in patients with relapsed or refractory CD19+ aggressive non-hodgkin lymphoma at the 2017 Annual Meeting of the American Society for Clinical Oncology (ASCO).
Teva Pharmaceutical Industries has reported positive results from a Phase III HALO study for its migraine drug fremanezumab.
Biopharmaceutical firm Lysogene has completed enrollment of patients in its “Sanfilippo A Multi-national Observational Study” (SAMOS).
Neurocrine Biosciences said that the initial phase II Tourette syndrome T-Force GREEN study of INGREZZA (valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint.
Inovio Pharmaceuticals' Pennvax-GP HIV vaccine has demonstrated nearly 100% immune response rates in a clinical study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.